Talk:DMXE

File:Yellow-warning-sign1.svg

This page has not been fully approved by the PsychonautWiki administrators. It may contain incorrect information, particularly with respect to dosage, duration, subjective effects, toxicity and other risks. It may also not meet PW style and grammar standards.

Not to be confused with Methoxetamine.

Summary sheet: DMXE

{{#arraydefine: InhaledDosage | Threshold;, Light;, Common;, Strong;, Heavy; }} {{#arraydefine: InhaledDuration | Total;, Onset;, Come up;, Peak;, Offset;, After effects; }} {{#arraydefine: SmokedDosage | Threshold;, Light;, Common;, Strong;, Heavy; }} {{#arraydefine: SmokedDuration | Total;, Onset;, Come up;, Peak;, Offset;, After effects; }} {{#arraydefine: OralDosage | Threshold;, Light;, Common;, Strong;, Heavy; }} {{#arraydefine: OralDuration | Total;, Onset;, Come up;, Peak;, Offset;, After effects; }} {{#arraydefine: SublingualDosage | Threshold;, Light;, Common;, Strong;, Heavy; }} {{#arraydefine: SublingualDuration | Total;, Onset;, Come up;, Peak;, Offset;, After effects; }} {{#arraydefine: BuccalDosage | Threshold;, Light;, Common;, Strong;, Heavy; }} {{#arraydefine: BuccalDuration | Total;, Onset;, Come up;, Peak;, Offset;, After effects; }} {{#arraydefine: InsufflatedDosage | Threshold;Insufflated threshold dose::5Insufflated dose units::mg, Light;Insufflated min light dose::5 - Insufflated max light dose::20 mg, Common;Insufflated min common dose::20 - Insufflated max common dose::35 mg, Strong;Insufflated min strong dose::35 - Insufflated max strong dose::60 mg, Heavy;Insufflated heavy dose::60 mg + }} {{#arraydefine: InsufflatedDuration | Total;Insufflated min total time::2 - Insufflated max total time::6Insufflated total time units::hours, Onset;Insufflated min onset time::5 - Insufflated max onset time::15Insufflated onset time units::minutes, Come up;Insufflated min comeup time::30 - Insufflated max comeup time::90Insufflated comeup time units::minutes, Peak;Insufflated min peak time::1 - Insufflated max peak time::3Insufflated peak time units::hours, Offset;Insufflated min offset time::1 - Insufflated max offset time::2Insufflated offset time units::hours, After effects; }} {{#arraydefine: RectalDosage | Threshold;, Light;, Common;, Strong;, Heavy; }} {{#arraydefine: RectalDuration | Total;, Onset;, Come up;, Peak;, Offset;, After effects; }} {{#arraydefine: TransdermalDosage | Threshold;, Light;, Common;, Strong;, Heavy; }} {{#arraydefine: TransdermalDuration | Total;, Onset;, Come up;, Peak;, Offset;, After effects; }} {{#arraydefine: SubcutaneousDosage | Threshold;, Light;, Common;, Strong;, Heavy; }} {{#arraydefine: SubcutaneousDuration | Total;, Onset;, Come up;, Peak;, Offset;, After effects; }} {{#arraydefine: IntramuscularDosage | Threshold;, Light;, Common;, Strong;, Heavy; }} {{#arraydefine: IntramuscularDuration | Total;, Onset;, Come up;, Peak;, Offset;, After effects; }} {{#arraydefine: IntravenousDosage | Threshold;, Light;, Common;, Strong;, Heavy; }} {{#arraydefine: IntravenousDuration | Total;, Onset;, Come up;, Peak;, Offset;, After effects; }} {{#arraydefine: uncertaininteractions | {{#ask:DMXE |?UncertainInteraction |headers=hide |format=list |mainlabel=- |link=none }} }} {{#arraydefine: unsafeinteractions | {{#ask:DMXE |?UnsafeInteraction |headers=hide |format=list |mainlabel=- |link=none }} }} {{#arraydefine: dangerousinteractions | {{#ask:DMXE |?DangerousInteraction |headers=hide |format=list |mainlabel=- |link=none }} }} {{#arrayprint:uncertaininteractions||@@@@| }} {{#arrayprint:unsafeinteractions||@@@@| }} {{#arrayprint:dangerousinteractions||@@@@| }}

DMXE
File:DMXE.svg
Chemical Nomenclature
Common names	DMXE
Substitutive name	Deoxymethoxetamine
Systematic name	2-(ethylamino)-2-(3-methylphenyl)cyclohexan-1-one
Class Membership
Psychoactive class	Psychoactive class::Dissociative / Psychoactive class::Hallucinogen
Chemical class	chemical class::Arylcyclohexylamine
Routes of Administration
WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section. {{#arrayunique: InsufflatedDosage}} {{#loop: i | 0 | {{#arraysize: InsufflatedDosage}} | {{#arraydefine: val | {{#arrayindex: InsufflatedDosage | {{#var: i}} }} | ; }} }} {{#arrayunique: InsufflatedDuration}} {{#loop: i | 0 | {{#arraysize: InsufflatedDuration}} | {{#arraydefine: val | {{#arrayindex: InsufflatedDuration | {{#var: i}} }} | ; }} }} ⇣ Insufflated Dosage [[Dosage_classification#{{#arrayindex: val | 0 }}|{{#arrayindex: val | 0 }}]] {{#arrayindex: val | 1 }} Duration [[Duration#{{#arrayindex: val | 0 }}|{{#arrayindex: val | 0 }}]] {{#arrayindex: val | 1 }} DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.
Interactions
@@@@
@@@@
@@@@

DMXE (Deoxymethoxetamine)

3-Me-2'-oxo-PCE (also known as Deoxymethoxetamine, DMXE) is a psychoactive class::dissociative substance in the Chemical class::arylcyclohexylamine class. It produces ketamine-like dissociative effects and is structurally related to MXE, ketamine, PCE, and 3-MeO-PCP.

DMXE emerged in October 2020, marketed as a legal replacement for MXE following MXE's global ban.

Due to its limited history of human use, little is known about its long-term effects, metabolism, or toxicity. Harm reduction practices are strongly advised.

History and Culture

DMXE was first reported in 2020 and quickly gained popularity as an alternative to MXE. Alongside MXiPr, it has been sold online as a research chemical dissociative since October 2020.

DMXE is rarely sold on the streets and is almost exclusively found in online research chemical markets.

Chemistry

DMXE (Deoxymethoxetamine), or 2-(ethylamino)-2-(3-methylphenyl)-cyclohexanone, belongs to the arylcyclohexylamine family, which includes ketamine, PCP, and MXE.

Structural Differences from MXE

• DMXE lacks the 3-methoxy (-OCH₃) group of MXE, replacing it with a methyl (-CH₃) group instead.
• This makes DMXE less bulky and more hydrophobic, potentially altering its pharmacology.

Physical Properties

• DMXE is usually a light yellow-tan crystalline solid, often sandy or flaky in texture.
• It is sparingly soluble (10 mg/mL in ethanol or DMSO).
• Stability: ~5 years when stored at -20°C.

Comparison to 3D-MXE

• DMXE: Lighter (yellow-tan), more crystalline/sandy.
• 3D-MXE: Darker (brown/gray), finer, more powdery.

Pharmacology

DMXE acts as a non-competitive NMDA receptor antagonist. NMDARs (N-methyl-D-aspartate receptors) are specific types of glutamate receptors which modulate the transmission of electrical signals between neurons in the brain and spinal cord; for the signals to pass, the receptor must be open. The substance has shown a IC₅₀ (half-maximal inhibitory concentration), which measures the potency of DMXE and related compounds in blocking NMDARs, of 0.679mM, indicating significant potency. DMXE and related compounds bind to the phcyclidine (PCP) site of NMDARs, which was determined via in silico docking results. This binding is implicated in the antagonistic activity observed, which includes the blocking of NMDA-induced inward currents in a dose-dependent manner. DMXE shows a high affinity and potent inhibitory capacity comparable to that of other MXE analogs like MXiPr and O-desmethyl MXE, with some variations in potency explained by different interactions at the receptor site. Additionally, DMXE significantly reduces excitatory postsynaptic currents (EPSCs) evoked in the presence of NMDA.

Dissociatives inhibit the normal functioning NMDA receptors by binding to and blocking them. This disruption of neural network activity leads to loss of normal cognitive and affective processing, psychomotor functioning, anesthesia and eventually the equivalent of a “k-hole.”

Subjective effects

File:Metacogghjgjvghnition.png

This subjective effects section is a stub. As such, it is still in progress and may contain incomplete or wrong information. You can help by expanding or correcting it.

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

{{

 #fornumargs: number
 | column
 | 

{{#var: column}} }}

Experience reports

There are currently {{#ask: | format=count}} experience reports which describe the effects of this substance in our experience index. {{#ask: |format=ul|Columns=1}} Additional experience reports can be found here:

• Erowid Experience Vaults: DMXE

Toxicity and harm potential

Further information: Research chemicals § Toxicity and harm potential, and Responsible use

Due to its similarity to MXE, it is advised to use MXE's safety profile when taking this substance. The toxicity and long-term health effects of recreational DMXE use specifically have not been researched.

This is because DMXE is a research chemical with a very brief history of human usage.

It is strongly recommended that one use harm reduction practices when using this substance.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

• UncertainInteraction::DOx - As an NMDA antagonist MXE potentiates DOx which can be unpleasantly intense.
• UncertainInteraction::25x-NBOMe - As an NMDA antagonist MXE potentiates NBOMes which can be unpleasantly intense.
• UncertainInteraction::2C-T-x
• UncertainInteraction::PCP - There are no reports available about this combination.
• UncertainInteraction::Amphetamines - Risk of tachycardia, hypertension, and manic states.
• UncertainInteraction::MDMA - There have been reports of risky serotonergic interactions when the two are taken at the same time, but MXE taken to the end of an MDMA experience does not appear to cause the same issues.
• UncertainInteraction::Cocaine - Stimulants taken with MXE can lead to hypermanic states much more easily, especially if sleep is avoided.
• UncertainInteraction::Benzodiazepines - Both substances potentiate the ataxia and sedation caused by the other and can lead to unexpected loss of consciousness at high doses. Place affected patients in the recovery position to prevent vomit aspiration from excess.
• UncertainInteraction::SSRIs - Depending on the SSRI this combination can be unpredictable.
• UnsafeInteraction::MAOIs - MAO-B inhibitors appear to increase the potency of MXE. MAO-A inhbitors have some negative reports associated with the combination but there isn't much information available.
• DangerousInteraction::ΑMT
• DangerousInteraction::Alcohol - There is a high risk of memory loss, vomiting and severe ataxia from this combination.
• DangerousInteraction::GHB - Both substances cause ataxia and bring a risk of vomiting and unconsciousness. If the patient falls unconscious while under the influence there is a severe risk of vomit aspiration if they are not placed in the recovery position.
• DangerousInteraction::GBL - Both substances cause ataxia and bring a risk of vomiting and unconsciousness. If the patient falls unconscious while under the influence there is a severe risk of vomit aspiration if they are not placed in the recovery position.
• DangerousInteraction::Opioids - This combination can potentiate the effects of the opioid.
• DangerousInteraction::Tramadol

Legal status

• US: DMXE itself is not scheduled, but due to its similarities to now schedule I MXE, one can be prosecuted for under the Federal Analog Act, which states any chemical "substantially similar" to a controlled substance listed in Schedule I or II to be treated as if it were listed in Schedule I, but only if intended for human consumption.
• CA: DMXE is on Schedule 1 in Canada.
• DE: DMXE is regulated under the NpSG in Germany.
• UK: DMXE is scheduled under Class B in the United Kingdom.

See also

• Responsible use
• Research chemical
• Dissociatives
• Arylcyclohexylamines
• MXE
• PCP
• Ketamine

External links

(List along order below)

• DMXE (Wikipedia)
• DMXE (Erowid Vault)
• DMXE (Isomer Design)
• DMXE (PubChem)

Literature

• Irie, T., Yanase, Y., Demizu, Y., Usami, M., & Kikura-Hanajiri, R. (2022). Derivatives of methoxetamine and major methoxetamine metabolites potently block NMDA receptors. Journal of Pharmacological Sciences, 150(4), 233-243. https://doi.org/10.1016/j.jphs.2022.09.005